Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease

D.D. Sin*, B.E. Miller, A. Duvoix, S.F. Man, X. Zhang, E.K. Silverman, J.E. Connett, N.A. Anthonisen, R.A. Wise, D. Tashkin, B.R. Celli, L.D. Edwards, N. Locantore, W. MacNee, R. Tal-Singer, (incl. E. Wouters) ECLIPSE Investigators, D.A. Lomas

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


RATIONALE: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. OBJECTIVES: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. MEASUREMENTS AND MAIN RESULTS: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. CONCLUSIONS: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.
Original languageEnglish
Pages (from-to)1187-1192
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Issue number9
Publication statusPublished - 1 May 2011


  • biomarker
  • chronic obstructive pulmonary disease
  • PARC/CCL-18
  • chemokine
  • COPD
  • CCL18

Cite this